-

Agilent Names Philip Binns to Lead Life Sciences and Applied Markets Group

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies, Inc. (NYSE: A) today announced Philip Binns has been named president of the company’s Life Sciences and Applied Markets Group (LSAG). Binns previously served as vice president and general manager of the Spectroscopy and Vacuum Solutions Division for LSAG. Binns replaces Jacob Thaysen who left the company effective today.

“We’re extremely pleased to have someone with Phil’s knowledge, experience and proven leadership strengths heading up our LSAG business,” said Mike McMullen, Agilent president and CEO. “I’m confident he will drive continued success for LSAG and Agilent. At the same time, I’d like to thank Jacob for his contributions to Agilent over the years.”

Binns joined Agilent in 2010 as part of the company’s acquisition of Varian, Inc. His strategic vision and focus on execution have been key to transforming Agilent’s spectroscopy business into its current market leading position. With his exceptional leadership skills and deep market knowledge, Binns has earned increasing levels of responsibility during his tenure at both Agilent and Varian.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers’ most challenging questions. The company generated revenue of $6.85 billion in fiscal 2022 and employs 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to the Agilent Newsroom.

Follow Agilent on LinkedIn and Facebook.

Contacts

Media Contact:
Tom Beermann
Agilent Technologies
tom.beermann@agilent.com

Investor Contact:
Parmeet Ahuja
Agilent Technologies
parmeet_ahuja@agilent.com

Agilent Technologies Inc.

NYSE:A
Details
Headquarters: Santa Clara, California, USA
CEO: Padraig McDonnell
Employees: 18000
Organization: PUB

Release Versions

Contacts

Media Contact:
Tom Beermann
Agilent Technologies
tom.beermann@agilent.com

Investor Contact:
Parmeet Ahuja
Agilent Technologies
parmeet_ahuja@agilent.com

More News From Agilent Technologies Inc.

Agilent Showcases Advances in Precision Oncology and Digital Pathology at USCAP 2026

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced it will feature its latest advances in precision oncology and digital pathology workflows at the 2026 United States and Canadian Academy of Pathology (USCAP) Annual Meeting, taking place March 21-26 in San Antonio, Texas. Agilent will highlight expanded biomarker testing capabilities, continued progress in digital pathology adoption, and the evolving role of the Dako Omnis family of instruments as a founda...

Agilent Launches Agilent Advanced Therapeutics, Unifying CDMO Capabilities Across Canada and United States

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the launch of Agilent Advanced Therapeutics, a unified Contract Development and Manufacturing Organization (CDMO) solution integrating the company’s expanding capabilities across Canada and the United States. Agilent Advanced Therapeutics brings together the strengths of BIOVECTRA in Canada and Nucleic Acid Solutions in Colorado to deliver a full suite of premium, scalable and customizable manufacturing so...

Agilent to Acquire Biocare Medical, a Global Leader in Clinical and Research Pathology Solutions

SANTA CLARA, Calif. & SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced it has entered into a definitive agreement to acquire Biocare Medical, a global leader in clinical pathology, from an investor group led by Excellere Partners and GHO Capital Partners LLP, in an all-cash transaction valued at $950 million. Biocare is a high-growth global pathology antibody leader, serving customers with a complementary portfolio of immunohistochemistry (IHC), in sit...
Back to Newsroom